Insight Molecular Diagnostics Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) operates as a precision diagnostics company focused on molecular testing for oncology and transplantation. The company develops and commercializes laboratory-developed tests, research-use-only (RUO) kitted assays, and in-vitro diagnostic (IVD) test kits, including GraftAssureCore, a laboratory-developed test quantifying donor-derived cell-free DNA (dd-cfDNA) for kidney transplant monitoring reimbursed by Medicare; GraftAssureIQ, an RUO blood-based dd-cfDNA test kit; GraftAssureDx, an IVD test kit in development for FDA submission by year-end 2025 to enable decentralized kidney transplant rejection testing; VitaGraft Kidney and VitaGraft Liver, blood-based dd-cfDNA tests for kidney and liver transplantation; DetermaCNI, a blood-based test measuring genomic copy number instability in circulating tumor DNA to monitor cancer treatment efficacy; DetermaIO, a 27-gene expression laboratory-developed test assessing the tumor microenvironment to predict immunotherapy response; and testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. It maintains a collaboration with Bio-Rad Laboratories, Inc. for development and commercialization of RUO and IVD kitted transplant products using Bio-Rad's ddPCR instruments and reagents; operates a CLIA-certified laboratory in Nashville, Tennessee, and a laboratory and R&D center in Gottingen, Germany; and serves researchers, clinicians, hospitals, and healthcare systems in the United States and internationally. Founded in 2009 and headquartered at 2 International Plaza Drive, Suite 510, Nashville, Tennessee, the company changed its name from OncoCyte Corporation in June 2025 and relocated its principal executive offices from Irvine, California, to Nashville to align with its expanded focus on transplant medicine. Recent developments include advancing toward a 2026 commercial launch of GraftAssureDx with 11 clinical trial sites such as Vanderbilt University Medical Center and Cleveland Clinic collecting samples for FDA submission, engaging 19 transplant centers globally through clinical trials and GraftAssureIQ research, launching a 5,000-participant multi-center registry study to generate real-world data across 50 centers, publishing data demonstrating GraftAssure's utility in monitoring kidney transplant patients during CAR-T therapy, preparing expansions into heart and lung transplant testing with early favorable heart rejection detection data, appointing Steven Tahmooressi as Vice President of Marketing in September 2025 to lead commercialization, and reporting Q3 2025 results with on-track progress toward 20 transplant center engagements by year-end despite a federal government shutdown potentially impacting FDA timelines.
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio
IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper
iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry
IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation
IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation
Insight Molecular Diagnostics Inc. (IMDX) Shareholder/Analyst Call Prepared Remarks Transcript
iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress
Insight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings Call Transcript
IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization
Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay
Insight Molecular Diagnostics Inc. (IMDX) Q4 2025 Earnings Call Transcript
IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results
iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference
Second Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model Score
Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head-To-Head Review
Head-To-Head Contrast: Oncocyte (NASDAQ:IMDX) vs. Anbio Biotechnology (NASDAQ:NNNN)
Head-To-Head Analysis: Oncocyte (NASDAQ:IMDX) & Anbio Biotechnology (NASDAQ:NNNN)
Financial Comparison: Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX)
Analyzing Anbio Biotechnology (NASDAQ:NNNN) & Oncocyte (NASDAQ:IMDX)